OPK Stock Overview
A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.58 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.85 |
| Beta | 1.65 |
| 11 Month Change | 5.33% |
| 3 Month Change | -0.63% |
| 1 Year Change | 3.27% |
| 33 Year Change | -59.07% |
| 5 Year Change | -3.66% |
| Change since IPO | -64.89% |
Recent News & Updates
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09
Recent updates
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09Not Enough To Keep OPKO Health Flying
Aug 28OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05OPKO Health Is Risky But Might Make You Money
Mar 29Shareholder Returns
| OPK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 1.6% |
| 1Y | 3.3% | 7.5% | 32.3% |
Return vs Industry: OPK underperformed the US Healthcare industry which returned 7.5% over the past year.
Return vs Market: OPK underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| OPK volatility | |
|---|---|
| OPK Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OPK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OPK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3,930 | Phil Frost | www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
| OPK fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$133.73m |
| Revenue (TTM) | US$711.41m |
1.5x
P/S Ratio-8.1x
P/E RatioIs OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPK income statement (TTM) | |
|---|---|
| Revenue | US$711.41m |
| Cost of Revenue | US$627.03m |
| Gross Profit | US$84.38m |
| Other Expenses | US$218.11m |
| Earnings | -US$133.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 11.86% |
| Net Profit Margin | -18.80% |
| Debt/Equity Ratio | 31.4% |
How did OPK perform over the long term?
See historical performance and comparison